AGC (Asahi Glass Co Ltd) (TYO:5201) solves everyday challenges with its world-leading, cutting-edge technologies. Using the world's top-class technologies cultivated through a history of technological innovation extending over 100 years, AGC has continued to achieve the creation of new values in the business areas of Glass, Electronics, Chemicals, and Ceramics.
Regeneus Ltd (ASX:RGS) CEO John Martin talks on the release of the financial results following the company's significant progress with Japanese partner Asahi Glass Ltd (AGC) (TYO:5201)
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Full-Year Report for the 12 months ending 30 June 2017.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced that it has entered into a strategic collaboration and licensing agreement with AGC Asahi Glass (AGC) (TYO:5201), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals.
Asian Activities Report for December 16, 2011 includes: Asahi Glass Co., Ltd. (TYO:5201) will establish a new cathode materials production and sales site in China for lithium-ion batteries used in mobile devices and electronic vehicles; FUJIFILM Holdings Corporation (TYO:4901) has signed a definitive agreement to acquire all outstanding shares of SonoSite, Inc. (NASDAQ:SONO) for approximately US$995 million; Kobe Steel, Ltd. (TYO:5406) plans to increase the production capacity of its Chinese subsidiary which makes aluminum forgings for automotive suspensions; Eisai Co., Ltd. (TYO:4523) has received approval from Health Canada for Halaven(TM), a novel anticancer agent for the treatment of metastatic breast cancer.
